Veozah (fezolinetant) — Point32Health

Initial criteria

• Diagnosis of moderate to severe vasomotor symptoms due to menopause
• AND Trial and failure, contraindication, or intolerance to a drug from both of the following classes:
• A. Menopausal hormone therapy (e.g., Premarin, Bijuva, Estrogel, etc.)
• B. Non-hormonal therapy (e.g., paroxetine mesylate, venlafaxine, clonidine, gabapentin, etc.)

Reauthorization criteria

• First Reauthorization: Documentation the Member had follow-up laboratories to assess hepatic function AND documentation Member has been reassessed for this condition within the previous six months, has demonstrated a positive response to therapy, and treatment with Veozah continues to be medically necessary
• Subsequent Reauthorizations: Documentation the Member has been reassessed for this condition within the previous year, has demonstrated a positive response to therapy, and treatment with Veozah continues to be medically necessary

Approval duration

initial 6 months; reauth 12 months